- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
This study is being conducted to evaluate the combination of enfortumab vedotin + pembrolizumab versus standard of care concurrent chemoradiotherapy, in subjects with previously untreated muscle invasive bladder cancer.
Enfortumab vedotin may be administered for up to 9 cycles or a protocol defined reason for study discontinuation occurs, whichever is first. Pembrolizumab may be administered for a maximum of 17 cycles (3-week cycles) or a protocol-defined reason for study discontinuation occurs, whichever is first. Concurrent chemoradiotherapy may be administered for a maximum of 6.5 weeks.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Pfizer CT.gov Call Center
- Telefoonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studie Locaties
-
-
Quebec
-
Chicoutimi, Quebec, Canada
- Werving
- Site CA01194
-
Montreal, Quebec, Canada
- Werving
- Site CA01071
-
Montreal, Quebec, Canada
- Werving
- Site CA01052
-
-
-
-
-
Kaohsiung City, Taiwan
- Werving
- Site TW01117
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72211
- Werving
- Arkansas Urology
-
-
California
-
Santa Barbara, California, Verenigde Staten, 93105
- Werving
- Samsun Clinic - Ridley-Tree Cancer Center
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80012
- Werving
- Rocky Mountain Cancer Center
-
-
Delaware
-
Newark, Delaware, Verenigde Staten, 19713
- Werving
- Medical Oncology Hematology Consultants
-
-
Illinois
-
Hinsdale, Illinois, Verenigde Staten, 60521
- Werving
- Hope and Healing Clinical Research LLC
-
New Lenox, Illinois, Verenigde Staten, 60451
- Werving
- Hope and Healing Clinical Research LLC
-
Niles, Illinois, Verenigde Staten, 60714
- Werving
- Illinois Cancer Specialists
-
-
Indiana
-
Fort Wayne, Indiana, Verenigde Staten, 46825
- Werving
- Fort Wayne Medical Oncology and Hematology
-
-
Michigan
-
Royal Oak, Michigan, Verenigde Staten, 48073
- Werving
- Comprehensive Urology
-
-
Missouri
-
Columbia, Missouri, Verenigde Staten, 65201
- Werving
- Missouri Cancer Associates
-
St Louis, Missouri, Verenigde Staten, 63110
- Werving
- Siteman Cancer Center
-
-
Nevada
-
Las Vegas, Nevada, Verenigde Staten, 89106
- Werving
- Comprehensive Cancer Centers of Nevada - Southwest
-
-
New York
-
New York, New York, Verenigde Staten, 10029
- Werving
- Icahn School of Medicine at Mount Sinai
-
-
Ohio
-
Fairfield, Ohio, Verenigde Staten, 45014
- Werving
- Oncology Hematology Care Clinical Trials, LLC
-
-
Oregon
-
Eugene, Oregon, Verenigde Staten, 97401
- Werving
- Williamette Valley Cancer Institute and Research Center
-
Tigard, Oregon, Verenigde Staten, 97223
- Werving
- Compass Oncology - West
-
-
Tennessee
-
Nashville, Tennessee, Verenigde Staten, 37203
- Werving
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78705
- Werving
- Texas Oncology
-
Tyler, Texas, Verenigde Staten, 75702
- Werving
- Texas Oncology - Northeast Texas
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22903
- Werving
- University of Virginia Comprehensive Cancer Center
-
Norfolk, Virginia, Verenigde Staten, 23502
- Werving
- Virginia Oncology Associates
-
-
-
-
-
Daegu, Zuid -Korea
- Werving
- Site KR01113
-
Seongnam-si, Zuid -Korea
- Werving
- Site KR01063
-
Seoul, Zuid -Korea
- Werving
- Site KR01065
-
Seoul, Zuid -Korea
- Werving
- Site KR01084
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Has histologically confirmed initial diagnosis of muscle-invasive bladder cancer (MIBC) with predominant urothelial histology staged cT2-T4aN0M0
- Tissue comprising muscle-invasive urothelial cancer must be submitted for clinical staging at baseline
- Eligible for and agree to receive chemoradiotherapy and one of the protocol-specified radiosensitizing chemotherapy regimens
- Fit for systemic therapy and elect bladder preservation, including participants who are ineligible for or have elected not to undergo cystectomy
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
Exclusion Criteria:
- Advanced or metastatic disease (N+, M1), non-urothelial carcinoma, diffuse or multifocal CIS, urothelial carcinoma or histological variant at any site outside the urinary bladder within previous 24 months prior to randomization except Ta/T1/CIS of the upper urinary tract including renal pelvis and ureter if the participant had undergone complete nephrectomy
- Has received any prior systemic treatment, chemoradiation, and/or radiation for MIBC or NMIBC
- Prior pelvic radiation for any reason
- Inadequate bladder function
- Other active malignancies within 3 years prior to randomization
- Previously treated with enfortumab vedotin or other MMAE-based antibody-drug conjugates (ADCs)
- Previously treated with a PD(L)-1 inhibitor, defined as a PD-1 inhibitor or PD-L1 inhibitor
- Uncontrolled diabetes
- Currently receiving systemic antimicrobial treatment for active infection (viral, bacterial, or fungal) at the time of randomization. Routine antimicrobial prophylaxis is permitted
- Known active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection
- Received major surgery (defined as requiring general anesthesia and >24 hour inpatient hospitalization) within 4 weeks prior to randomization
- Known severe (≥ Grade 3) hypersensitivity to any enfortumab vedotin excipient contained in the drug formulation of enfortumab vedotin
- Known genetic disorders associated with radiosensitivity (eg, ataxia telangiectasia, Nijmegen breakage syndrome, Fanconi syndrome)
- Active keratitis or corneal ulcerations
- History of autoimmune disease that has required systemic treatment in the past 2 years
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Prior allogeneic stem cell or solid organ transplant
- Received a live attenuated vaccine within 30 days prior to randomization
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A
Enfortumab vedotin + pembrolizumab (EV + P) |
Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.
Andere namen:
IV infusion on Day 1 of every 3-week cycle up to cycle 17.
Andere namen:
|
|
Actieve vergelijker: Arm B
Concurrent Chemoradiotherapy (cCRT) |
64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes. 55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only. 40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation. 500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.
Andere namen:
12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.
Andere namen:
100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)
Tijdsspanne: Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment confirmed by BICR, histologically confirmed recurrent MIBC by BICR, disease progression by BICR, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Overall Survival (OS)
Tijdsspanne: Up to approximately 60 months
|
Time from randomization to death due to any cause. |
Up to approximately 60 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Bladder-intact Event Free Survival (BI-EFS) by Investigator
Tijdsspanne: Up to approximately 45.5 months
|
BI-EFS is defined as the time from randomization to any of the following events: histologically confirmed persistent or residual MIBC post-treatment, histologically confirmed recurrent MIBC, disease progression, cystectomy, or death from any cause. |
Up to approximately 45.5 months
|
|
Complete clinical response (cCR) rate by Blinded Independent Central Review (BICR) and Investigator
Tijdsspanne: Up to approximately 60 months
|
cCR is defined as no radiographic evidence of residual or metastatic disease on imaging, negative cystoscopy, negative pathology except for low-grade Ta, and negative urine cytology. |
Up to approximately 60 months
|
|
Metastasis-Free Survival (MFS) by Blinded Independent Central Review (BICR) and Investigator
Tijdsspanne: Up to approximately 60 months]
|
Time from randomization to radiologically or pathologically confirmed distant metastasis, or death due to any cause, whichever occurs first. |
Up to approximately 60 months]
|
|
Time to Cystectomy
Tijdsspanne: Up to approximately 60 months
|
The time from randomization to cystectomy. |
Up to approximately 60 months
|
|
Disease Free Survival (DFS) by Blinded Independent Central Review (BICR) and Investigator
Tijdsspanne: Up to approximately 60 months
|
The time from cCR to local recurrence or distant metastases, a second primary bladder cancer, or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Cystectomy Free Survival (CFS)
Tijdsspanne: Up to approximately 60 months
|
The time from randomization to cystectomy or death due to any cause, whichever occurs first. |
Up to approximately 60 months
|
|
Number of Participants with Treatment Emergent Adverse Event (TEAE)
Tijdsspanne: From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
An AE is any untoward medical occurrence in a participant who receives a study treatment without regard to possibility of causal relationship. Treatment-emergent are events between the first dose of study treatment and up to 30 days after the last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of study treatment up to 30 days after last dose of study drug (approximately up to 1.1 years)
|
|
Number of Participants with Serious TEAEs
Tijdsspanne: From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
An SAE is any AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/ incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 90 days after last dose that were absent before treatment or that worsened relative to pretreatment state. |
From start of treatment up to 90 days after the last dose of study treatment (approximately up to 1.3 years)
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Studie directeur: Zejing Wang, MD/PhD, Pfizer
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
- Gemcitabine
- Neoplasmata
- Neoplasmata van de urineblaas
- Urotheelcarcinoom
- Cisplatine
- Pembrolizumab
- Fluoruracil
- Complicaties
- Urologische ziekten
- Urotheliale kanker
- Enfortumab vedotin
- Urogenitale neoplasmata
- Neoplasmata per site
- Urologische neoplasmata
- Vrouwelijke urogenitale ziekten
- Mannelijke urogenitale ziekten
- Spierinvasieve blaaskanker
- Mitomycine
- Ziekten van de urineblaas
- Blaas Behoud
- Urogenitale aandoeningen
- Female Urogenital Diseases and Pregnancy
- Bladder-sparing
Aanvullende relevante MeSH-voorwaarden
- Vrouwelijke urogenitale ziekten en zwangerschapscomplicaties
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Carcinoom
- Urogenitale ziekten
- Neoplasmata
- Urologische ziekten
- Neoplasmata van de urineblaas
- Urologische neoplasmata
- Carcinoom, overgangscel
- Urogenitale neoplasmata
- Neoplasmata per site
- Mannelijke urogenitale ziekten
- Ziekten van de urineblaas
- Vrouwelijke urogenitale ziekten
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Heterocyclische verbindingen, 2-ring
- Heterocyclische verbindingen, gefuseerd ring
- Therapeutica
- Indolen
- Anorganische chemicaliën
- Chloorverbindingen
- Stikstofverbindingen
- Deoxycytidine
- Cytidine
- Pyrimidine -nucleosiden
- Pyrimidines
- Uracil
- Pyrimidinonen
- Platinumverbindingen
- Radiotherapie
- Chinones
- Azirines
- Dosis fractionering, straling
- Radiotherapie dosering
- Mitomycines
- Indolequinonen
- Gemcitabine
- Fluorouracil
- Cisplatine
- Mitomycine
- pembrolizumab
- ENFORTUMAB VEDOTIN
- Hypofractionatie van stralingsdosis
Andere studie-ID-nummers
- C5701009
- EV-309 (Andere identificatie: Alias Study Number)
- 2026-525612-34-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .